|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Barta JA, Powell CA and Wisnivesky JP:
Global epidemiology of lung cancer. Ann Glob Health. 85:82019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zappa C and Mousa SA: Non-small cell lung
cancer: Current treatment and future advances. Transl Lung Cancer
Res. 5:288–300. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Spella M and Stathopoulos GT: Immune
resistance in lung adenocarcinoma. Cancers (Basel). 13:3842021.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu X, Nie L, Zhang Y, Yan Y, Wang C,
Colic M, Olszewski K, Horbath A, Chen X, Lei G, et al: Actin
cytoskeleton vulnerability to disulfide stress mediates
disulfidptosis. Nat Cell Biol. 25:404–414. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Machesky LM: Deadly actin collapse by
disulfidptosis. Nat Cell Biol. 25:375–376. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ren W, Zhao W, Cao L and Huang J:
Involvement of the actin machinery in programmed cell death. Front
Cell Dev Biol. 8:6348492021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang Y and Chang SKC: Color and texture
of surimi-like gels made of protein isolate extracted from catfish
byproducts are improved by washing and adding soy whey. J Food Sci.
87:3057–3070. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Franklin-Tong VE and Gourlay CW: A role
for actin in regulating apoptosis/programmed cell death: Evidence
spanning yeast, plants and animals. Biochem J. 413:389–404. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Smertenko A and Franklin-Tong VE:
Organisation and regulation of the cytoskeleton in plant programmed
cell death. Cell Death Differ. 18:1263–1270. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li Y, Jiang T, Zhou W, Li J, Li X, Wang Q,
Jin X, Yin J, Chen L, Zhang Y, et al: Pan-cancer characterization
of immune-related lncRNAs identifies potential oncogenic
biomarkers. Nat Commun. 11:10002020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Y, Zhang J, Huo C, Ding N, Li J, Xiao
J, Lin X, Cai B, Zhang Y and Xu J: Dynamic organization of lncRNA
and circular RNA regulators collectively controlled cardiac
differentiation in humans. EBioMedicine. 24:137–146. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huarte M: The emerging role of lncRNAs in
cancer. Nat Med. 21:1253–1261. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Luo J, Langer LF and Liu J: A novel role
of LncRNA in regulating tumor metabolism and angiogenesis under
hypoxia. Cancer Commun (Lond). 39:22019.PubMed/NCBI
|
|
15
|
Xu M, Zhou H, Hu P, Pan Y, Wang S, Liu L
and Liu X: Identification and validation of immune and oxidative
stress-related diagnostic markers for diabetic nephropathy by WGCNA
and machine learning. Front Immunol. 14:10845312023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Friedman J, Hastie T and Tibshirani R:
Regularization paths for generalized linear models via coordinate
descent. J Stat Softw. 33:1–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang M, Zheng H, Xu K, Yuan Q, Aihaiti Y,
Cai Y and Xu P: A novel signature to guide osteosarcoma prognosis
and immune microenvironment: Cuproptosis-related lncRNA. Front
Immunol. 13:9192312022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen Q, Sun T, Wang G, Zhang M, Zhu Y, Shi
X and Ding Z: Cuproptosis-related LncRNA signature for predicting
prognosis of hepatocellular carcinoma: A comprehensive analysis.
Dis Markers. 2022:32652122022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li H, Han D, Hou Y, Chen H and Chen Z:
Statistical inference methods for two crossing survival curves: A
comparison of methods. PLoS One. 10:e01167742015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang F, Lin H, Su Q and Li C:
Cuproptosis-related lncRNA predict prognosis and immune response of
lung adenocarcinoma. World J Surg Oncol. 20:2752022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Iasonos A, Schrag D, Raj GV and Panageas
KS: How to build and interpret a nomogram for cancer prognosis. J
Clin Oncol. 26:1364–1370. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu N, Hou J, Si J, Yang N, Chen B, Wei X
and Zhu L: SIRT1 and ZNF350 as novel biomarkers for osteoporosis: A
bioinformatics analysis and experimental validation. Mol Biol Rep.
51:5302024. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mayakonda A, Lin DC, Assenov Y, Plass C
and Koeffler HP: Maftools: Efficient and comprehensive analysis of
somatic variants in cancer. Genome Res. 28:1747–1756. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu J, Li L, Zhang H, Zhao Y, Zhang H, Wu S
and Xu B: A risk model developed based on tumor microenvironment
predicts overall survival and associates with tumor immunity of
patients with lung adenocarcinoma. Oncogene. 40:4413–4424. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang L, He YT, Dong S, Wei XW, Chen ZH,
Zhang B, Chen WD, Yang XR, Wang F, Shang XM, et al: Single-cell
transcriptome analysis revealed a suppressive tumor immune
microenvironment in EGFR mutant lung adenocarcinoma. J Immunother
Cancer. 10:e0035342022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Christgen S, Tweedell RE and Kanneganti
TD: Programming inflammatory cell death for therapy. Pharmacol
Ther. 232:1080102022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tan C, Du H, Wang Y, Zhao J, Cheng X and
Lan H: LncRNA GABPB1-IT1 inhibits the tumorigenesis of renal cancer
via the miR-21/PTEN axis. J Biochem Mol Toxicol. 37:e232882023.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cheng Z, Lu C, Wang H, Wang N, Cui S, Yu
C, Wang C, Zuo Q, Wang S, Lv Y, et al: Long noncoding RNA
LHFPL3-AS2 suppresses metastasis of non-small cell lung cancer by
interacting with SFPQ to regulate TXNIP expression. Cancer Lett.
531:1–13. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cui Y, Zhang C, Ma S and Guan F:
TFAP2A-induced SLC2A1-AS1 promotes cancer cell proliferation. Biol
Chem. 402:717–727. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang HB, Pan JY and Zhu T: A
disulfidptosis-related lncRNA prognostic model to predict survival
and response to immunotherapy in lung adenocarcinoma. Front
Pharmacol. 14:12541192023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Song Z, Cao X, Wang X, Li Y, Zhang W, Wang
Y and Chen L: A disulfidptosis-related lncRNA signature for
predicting prognosis and evaluating the tumor immune
microenvironment of lung adenocarcinoma. Sci Rep. 14:46212024.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang L, Liu J, Li S, Liu X, Zheng F, Xu S,
Fu B and Xiong J: Based on disulfidptosis, revealing the prognostic
and immunological characteristics of renal cell carcinoma with
tumor thrombus of vena cava and identifying potential therapeutic
target AJAP1. J Cancer Res Clin Oncol. 149:9787–9804. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao S, Wang L, Ding W, Ye B, Cheng C,
Shao J, Liu J and Zhou H: Crosstalk of disulfidptosis-related
subtypes, establishment of a prognostic signature and immune
infiltration characteristics in bladder cancer based on a machine
learning survival framework. Front Endocrinol (Lausanne).
14:11804042023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhou SZ, Pan YL, Deng QC, Yin CJ, Zhou DJ,
Liu ML, Zhou J and Wu XJ: A prognostic signature for colon
adenocarcinoma patients based on m6A-related lncRNAs. J Oncol.
2023:77977102023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yao J, Chen X, Liu X, Li R, Zhou X and Qu
Y: Characterization of a ferroptosis and iron-metabolism related
lncRNA signature in lung adenocarcinoma. Cancer Cell Int.
21:3402021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jiao Y, Zhou J, Jin Y, Yang Y, Song M,
Zhang L, Zhou J and Zhang J: Long non-coding RNA TDRKH-AS1
promotes colorectal cancer cell proliferation and invasion through
the β-Catenin activated Wnt signaling pathway. Front Oncol.
10:6392020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li H, Mu Q, Zhang G, Shen Z, Zhang Y, Bai
J, Zhang L, Zhou D, Zheng Q, Shi L, et al: Linc00426 accelerates
lung adenocarcinoma progression by regulating miR-455-5p as a
molecular sponge. Cell Death Dis. 11:10512020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fan Z, Wang Y and Niu R: Identification of
the three subtypes and the prognostic characteristics of stomach
adenocarcinoma: Analysis of the hypoxia-related long non-coding
RNAs. Funct Integr Genomics. 22:919–936. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang C, Bai X, Peng X, Shi W, Li Y, Chen
G, Yu H, Feng Z and Deng Y: Starvation-induced long non-coding RNAs
are significant for prognosis evaluation of bladder cancer. Aging
(Albany NY). 14:10067–10080. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hwang C, Lee SJ, Lee JH, Kim KH, Suh DS,
Kwon BS and Choi KU: Stromal tumor-infiltrating lymphocytes
evaluated on H&E-stained slides are an independent prognostic
factor in epithelial ovarian cancer and ovarian serous carcinoma.
Oncol Lett. 17:4557–4565. 2019.PubMed/NCBI
|
|
42
|
Paijens ST, Vledder A, de Bruyn M and
Nijman HW: Tumor-infiltrating lymphocytes in the immunotherapy era.
Cell Mol Immunol. 18:842–859. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shaban M, Khurram SA, Fraz MM, Alsubaie N,
Masood I, Mushtaq S, Hassan M, Loya A and Rajpoot NM: A novel
digital score for abundance of tumour infiltrating lymphocytes
predicts disease free survival in oral squamous cell carcinoma. Sci
Rep. 9:133412019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pan X, Lin H, Han C, Feng Z, Wang Y, Lin
J, Qiu B, Yan L, Li B, Xu Z, et al: Computerized tumor-infiltrating
lymphocytes density score predicts survival of patients with
resectable lung adenocarcinoma. iScience. 25:1056052022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xue Q, Wang Y, Zheng Q, Chen L, Lin Y, Jin
Y, Shen X and Li Y: Prognostic value of tumor immune
microenvironment factors in patients with stage I lung
adenocarcinoma. Am J Cancer Res. 13:950–963. 2023.PubMed/NCBI
|
|
46
|
Liu X, Wu S, Yang Y, Zhao M, Zhu G and Hou
Z: The prognostic landscape of tumor-infiltrating immune cell and
immunomodulators in lung cancer. Biomed Pharmacother. 95:55–61.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu C, Zheng S, Wang Z, Wang S, Wang X,
Yang L, Xu H, Cao Z, Feng X, Xue Q, et al: KRAS-G12D mutation
drives immune suppression and the primary resistance of
anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer. Cancer
Commun (Lond). 42:828–847. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wen Y, Tang F, Tu C, Hornicek F, Duan Z
and Min L: Immune checkpoints in osteosarcoma: Recent advances and
therapeutic potential. Cancer Lett. 547:2158872022. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Jardim DL, Goodman A, de Melo Gagliato D
and Kurzrock R: The challenges of tumor mutational burden as an
immunotherapy biomarker. Cancer Cell. 39:154–173. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Liu L, Bai X, Wang J, Tang XR, Wu DH, Du
SS, Du XJ, Zhang YW, Zhu HB, Fang Y, et al: Combination of TMB and
CNA stratifies prognostic and predictive responses to immunotherapy
across metastatic cancer. Clin Cancer Res. 25:7413–7423. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Samstein RM, Lee CH, Shoushtari AN,
Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ,
Omuro A, et al: Tumor mutational load predicts survival after
immunotherapy across multiple cancer types. Nat Genet. 51:202–206.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ricciuti B, Wang X, Alessi JV, Rizvi H,
Mahadevan NR, Li YY, Polio A, Lindsay J, Umeton R, Sinha R, et al:
Association of high tumor mutation burden in non-small cell lung
cancers with increased immune infiltration and improved clinical
outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA
Oncol. 8:1160–1168. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Cao D, Xu H, Xu X, Guo T and Ge W: High
tumor mutation burden predicts better efficacy of immunotherapy: A
pooled analysis of 103078 cancer patients. Oncoimmunology.
8:e16292582019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Imyanitov EN, Iyevleva AG and Levchenko
EV: Molecular testing and targeted therapy for non-small cell lung
cancer: Current status and perspectives. Crit Rev Oncol Hematol.
157:1031942021. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Shaw AT, Bauer TM, de Marinis F, Felip E,
Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, et al:
First-line lorlatinib or crizotinib in advanced ALK-positive lung
cancer. N Engl J Med. 383:2018–2029. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Abdelgalil AA, Al-Kahtani HM and
Al-Jenoobi FI: Erlotinib. Profiles Drug Subst Excip Relat Methodol.
45:93–117. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Lee TS, Kim JY, Lee MH, Cho IR, Paik WH,
Ryu JK, Kim YT and Lee SH: Savolitinib: A promising targeting agent
for cancer. Cancers (Basel). 15:47082023. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ni L, Yang H, Wu X, Zhou K and Wang S: The
expression and prognostic value of disulfidptosis progress in lung
adenocarcinoma. Aging (Albany NY). 15:7741–7759. 2023.PubMed/NCBI
|
